

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number  
**WO 2004/052878 A2**

(51) International Patent Classification<sup>7</sup>: **C07D 333/00**

(21) International Application Number:  
PCT/EP2003/013800

(22) International Filing Date: 4 December 2003 (04.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0228533.6 6 December 2002 (06.12.2002) GB

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DELL'ORCO, Phillip, C** [US/US]; GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 14906 (US). **KELLY, Henry, Anderson** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **SHAH,**

**Gita, Punjabhal** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **WATSON, Nigel, Stephen** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). **YOUNG, Robert, John** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).


(74) Agent: **BAKER, Suzanne, Jane**; GlaxoSmithKline, Corporate Intellectual Property CN925.1, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: CRYSTALLINE FORM



X-Ray Powder Diffractogram of substantially crystalline Example 2

(57) Abstract: (E)-2-(5-Chlorothien-2-yl)-N-[(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl]ethene-sulfonamide in substantially crystalline form, pharmaceutical formulations thereof, processes for preparing it, and its use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

WO 2004/052878 A2